In cauda venenum ou de l’importance de (la) TET(2)

Thomas Mercher; Cyril Quivoron; Lucile Couronné; William Vainchenker; Christian Bastard; Olivier A. Bernard

doi:10.1051/medsci/20112712009

Accès gratuit

Numéro		Med Sci (Paris) Volume 27, Numéro 12, Décembre 2011


Page(s)		1064 - 1066
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20112712009
Publié en ligne		23 décembre 2011

Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009 ; 324 : 930–935. [CrossRef] [PubMed]
Gu TP, Guo F, Yang H, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011 ; 477 : 606–610. [CrossRef] [PubMed]
Dawlaty MM, Ganz K, Powell BE, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011 ; 9 : 166–175. [CrossRef] [PubMed]
Nabel CS, Kohli RM. Molecular biology. Demystifying DNA demethylation. Science 2011 ; 333 : 1229–1230. [CrossRef] [PubMed]
Guo JU, Su Y, Zhong C, et al. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011 ; 10 : 2662–2668. [CrossRef] [PubMed]
Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007 ; 67 : 946–950. [CrossRef] [PubMed]
Münzel M, Globisch D, Carell T. 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 2011 ; 50 : 6460–6468. [CrossRef] [PubMed]
Bernard OA, Delhommeau F, Fontenay M, Vainchenker W. Mutations du gène TET2 dans les hémopathies myéloïdes humaines. Med Sci (Paris) 2009 ; 25 : 785–788. [CrossRef] [EDP Sciences] [PubMed]
Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011 ; 20 : 11–24. [CrossRef] [PubMed]
Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 ; 20 : 25–38. [CrossRef] [PubMed]
Li Z, Cai X, Cai C, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011 ; 118 : 4509–4518. [CrossRef] [PubMed]
Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011 ; 108 : 14566–14571. [CrossRef]
Viguie F, Aboura A, Bouscary D, et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 2005 ; 19 : 1411–1415. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009 ; 324 : 930–935. [CrossRef] [PubMed]

[2] Gu TP, Guo F, Yang H, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011 ; 477 : 606–610. [CrossRef] [PubMed]

[3] Dawlaty MM, Ganz K, Powell BE, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011 ; 9 : 166–175. [CrossRef] [PubMed]

[4] Nabel CS, Kohli RM. Molecular biology. Demystifying DNA demethylation. Science 2011 ; 333 : 1229–1230. [CrossRef] [PubMed]

[5] Guo JU, Su Y, Zhong C, et al. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 2011 ; 10 : 2662–2668. [CrossRef] [PubMed]

[6] Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007 ; 67 : 946–950. [CrossRef] [PubMed]

[7] Münzel M, Globisch D, Carell T. 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 2011 ; 50 : 6460–6468. [CrossRef] [PubMed]

[8] Bernard OA, Delhommeau F, Fontenay M, Vainchenker W. Mutations du gène TET2 dans les hémopathies myéloïdes humaines. Med Sci (Paris) 2009 ; 25 : 785–788. [CrossRef] [EDP Sciences] [PubMed]

[9] Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011 ; 20 : 11–24. [CrossRef] [PubMed]

[10] Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 ; 20 : 25–38. [CrossRef] [PubMed]

[11] Li Z, Cai X, Cai C, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011 ; 118 : 4509–4518. [CrossRef] [PubMed]

[12] Ko M, Bandukwala HS, An J, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011 ; 108 : 14566–14571. [CrossRef]

[13] Viguie F, Aboura A, Bouscary D, et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 2005 ; 19 : 1411–1415. [CrossRef] [PubMed]